<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Thermo Fisher Scientific Inc — News on 6ix</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc</link>
<description>Latest news and press releases for Thermo Fisher Scientific Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/thermo-fisher-scientific-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb3278dffbe2df11d0e8.webp</url>
<title>Thermo Fisher Scientific Inc</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc</link>
</image>
<item>
<title>Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-signs-agreement-to-sell-its-microbiology-business-to-astorg</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-signs-agreement-to-sell-its-microbiology-business-to-astorg</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 27, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.</description>
</item>
<item>
<title>Thermo Fisher Scientific Reports First Quarter 2026 Results</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-reports-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-reports-first-quarter-2026-results</guid>
<pubDate>Thu, 23 Apr 2026 10:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 23, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.</description>
</item>
<item>
<title>Biotechnology Instruments Market Analysis Report 2026-2035: Unified Frameworks Combining Genomics and Proteomics Underpin New Strategic Market Developments</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/biotechnology-instruments-market-analysis-report-2026-2035-unified-frameworks-combining-genomics-and-proteomics-underpin-new-strategic-market-developments</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/biotechnology-instruments-market-analysis-report-2026-2035-unified-frameworks-combining-genomics-and-proteomics-underpin-new-strategic-market-developments</guid>
<pubDate>Tue, 21 Apr 2026 10:12:00 GMT</pubDate>
<description>The biotechnology instruments market is growing due to personalized medicine, genomics, and molecular diagnostics. Opportunities lie in integrated multi-omics platforms and automation. Challenges include high costs. North America leads the market, with key players like Thermo Fisher and Danaher dominating. Biotechnology Instruments Market Biotechnology Instruments Market Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Biotechnology Instruments Market Size, Industry Dynamics, Opportunity Analysis</description>
</item>
<item>
<title>Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-applied-biosystemstm-powerflextm-thermal-cycler-to-advance-pcr-flexibility-and-productivity</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-applied-biosystemstm-powerflextm-thermal-cycler-to-advance-pcr-flexibility-and-productivity</guid>
<pubDate>Thu, 16 Apr 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., April 16, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex PC</description>
</item>
<item>
<title>Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientifics-ppd-clinical-research-business-collaborates-with-healthverity-to-expand-real-world-data-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientifics-ppd-clinical-research-business-collaborates-with-healthverity-to-expand-real-world-data-capabilities</guid>
<pubDate>Mon, 13 Apr 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., April 13, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors.</description>
</item>
<item>
<title>NovogeneAIT Genomics Appointed as Service Provider to Advance Large-Scale Proteomics for PRECISE-SG100K Cohort in Singapore</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/novogeneait-genomics-appointed-as-service-provider-to-advance-large-scale-proteomics-for-precise-sg100k-cohort-in-singapore</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/novogeneait-genomics-appointed-as-service-provider-to-advance-large-scale-proteomics-for-precise-sg100k-cohort-in-singapore</guid>
<pubDate>Fri, 10 Apr 2026 04:44:00 GMT</pubDate>
<description>NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by Thermo Fisher Scientific in collaboration with PRECISE to support precision medicine research in Singapore.</description>
</item>
<item>
<title>Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-expands-global-biobank-leadership-through-strategic-collaboration-with-precise-sg100k-singapore-to-advance-population-scale-proteomics</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-expands-global-biobank-leadership-through-strategic-collaboration-with-precise-sg100k-singapore-to-advance-population-scale-proteomics</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 09, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicatio</description>
</item>
<item>
<title>Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology</guid>
<pubDate>Tue, 07 Apr 2026 13:00:00 GMT</pubDate>
<description>Bethlehem, PA, April 07, 2026 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, today announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that support clinicians in optimizing patient outcomes. Under the agreement, Thermo Fisher will distribute Saladax therapeutic drug monitoring (TDM) tests through its established global commercial organization. The p</description>
</item>
<item>
<title>Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-integrated-platform-to-accelerate-biologics-development</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-integrated-platform-to-accelerate-biologics-development</guid>
<pubDate>Wed, 01 Apr 2026 12:15:00 GMT</pubDate>
<description>WALTHAM, Mass., April 01, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability.</description>
</item>
<item>
<title>Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-to-hold-earnings-conference-call-on-thursday-april-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-to-hold-earnings-conference-call-on-thursday-april-23-2026</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 01, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2026 before the market opens on Thursday, April 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.</description>
</item>
<item>
<title>Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-thermo-scientific-glacios-3-cryo-tem</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-thermo-scientific-glacios-3-cryo-tem</guid>
<pubDate>Tue, 31 Mar 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., March 31, 2026--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis.</description>
</item>
<item>
<title>Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-and-shl-medical-collaborate-to-deliver-fully-integrated-drug-device-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-and-shl-medical-collaborate-to-deliver-fully-integrated-drug-device-solutions</guid>
<pubDate>Wed, 25 Mar 2026 12:15:00 GMT</pubDate>
<description>RIDGEFIELD, N.J., March 25, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device com</description>
</item>
<item>
<title>Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-completes-acquisition-of-clario-holdings-inc</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-completes-acquisition-of-clario-holdings-inc</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., March 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services</description>
</item>
<item>
<title>Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies</guid>
<pubDate>Thu, 05 Mar 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 05, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies.</description>
</item>
<item>
<title>Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-new-color-based-chromogenic-culture-media-to-help-detect-candida-infections-faster-including-drug-resistant-candida-auris</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-launches-new-color-based-chromogenic-culture-media-to-help-detect-candida-infections-faster-including-drug-resistant-candida-auris</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>WALTHAM, Mass., March 02, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1.</description>
</item>
<item>
<title>Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-introduces-new-laboratory-developed-test-to-help-transplant-patients-receive-the-right-dose-of-critical-anti-rejection-medication-sooner</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-introduces-new-laboratory-developed-test-to-help-transplant-patients-receive-the-right-dose-of-critical-anti-rejection-medication-sooner</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>WEST HILLS, Calif., February 26, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection.</description>
</item>
<item>
<title>Thermo Fisher Scientific Increases Quarterly Dividend</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-increases-quarterly-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-increases-quarterly-dividend</guid>
<pubDate>Wed, 25 Feb 2026 21:15:00 GMT</pubDate>
<description>WALTHAM, Mass., February 25, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43.</description>
</item>
<item>
<title>Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-to-present-at-raymond-james-annual-institutional-investors-conference</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/thermo-fisher-scientific-to-present-at-raymond-james-annual-institutional-investors-conference</guid>
<pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., February 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET).</description>
</item>
<item>
<title>Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/next-generation-sequencing-market-competitive-landscape-report-2025-featuring-top-players-thermo-fisher-scientific-pacific-biosciences-illumina-roche</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/next-generation-sequencing-market-competitive-landscape-report-2025-featuring-top-players-thermo-fisher-scientific-pacific-biosciences-illumina-roche</guid>
<pubDate>Tue, 24 Feb 2026 11:34:00 GMT</pubDate>
<description>The Next-Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, applications in genomics and personalized medicine, and increased biotech investments. NGS revolutionizes DNA sequencing by rapidly reading millions of genome fragments, enhancing research in genomics, cancer, and infectious diseases. Major players like Illumina, Thermo Fisher Scientific, and</description>
</item>
<item>
<title>Life Science Precision Parts Research Report 2025: A $13.92 Billion Market by 2030 Featuring Key Players - Gemsons, Arc, Precision Resource, Thermo Fisher Scientific, Stryker, Linamar, TS Prototypes</title>
<link>https://6ix.com/company/thermo-fisher-scientific-inc/news/life-science-precision-parts-research-100800465</link>
<guid isPermaLink="true">https://6ix.com/company/thermo-fisher-scientific-inc/news/life-science-precision-parts-research-100800465</guid>
<pubDate>Tue, 17 Feb 2026 10:08:00 GMT</pubDate>
<description>The Life Science Precision Parts Market is set to expand from USD 9.50 billion in 2024 to USD 13.92 billion by 2030, at a CAGR of 6.57%. Key players like Knowles Corporation, Precipart, and Accumold are advancing in micromanufacturing for medtech applications. Automation is significantly transforming the sector, highlighting the need for precision components in genomics and molecular diagnostics. North America leads the market, driven by strong healthcare infrastructure and compliance standards.</description>
</item>
</channel>
</rss>